FINALLY, ANNULAR CLOSURE IS BEING USED IN THE U.S., AGAIN (Orthopedics This Week)
Barrachaid website
More than 500 patients have been treated with the newly FDA approved Barricaid annular closure device—in Europe.
Manufactured by Woburn, Massachusetts-based Intrinsic Therapeutics, Barricaid was tested in a European multicenter, randomized controlled trial involving 554 patients. The study outcomes led investigators to conclude that using Barricaid reduced the rate of recurrent symptomatic herniation by approximately 50% when compared to patients treated with discectomy alone.
The inaugural U.S. implant was performed by New York University’s Langone Health Center to repair a large annular defect. Jonathan R. Stieber, M.D., clinical assistant professor in the Department of Orthopedic Surgery, and Michael L. Smith, M.D., assistant professor in the Department of Neurosurgery and neurosurgeon at NYU Langone’s Spine Center, performed the initial procedure.
Barricaid is a titanium bone-anchored and polyester implant and is indicated for patients undergoing discectomy who suffer from radiculopathy and back pain due to herniated disc in the lower back.
“We’re excited to be the first in the ...
